Search Results - "Sukhin, Vladyslav"

Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) by Auranen, Annika, Powell, Matthew A, Sukhin, Vladyslav, Landrum, Lisa M, Ronzino, Graziana, Buscema, Joseph, Bauerschlag, Dirk, Lalisang, Roy, Bender, David, Gilbert, Lucy, Armstrong, Amy, Safra, Tamar, Nevadunsky, Nicole, Sebastianelli, Alexandra, Slomovitz, Brian, Ring, Kari, Coleman, Robert, Podzielinski, Iwona, Stuckey, Ashley, Teneriello, Michael, Gill, Sarah, Pothuri, Bhavana, Willmott, Lyndsay, Sharma, Sudarshan, Dabrowski, Christine, Antony, Grace, Stevens, Shadi, Mirza, Mansoor Raza, Fleming, Evelyn

“…In Part 1 of the phase III RUBY trial (NCT03981796) in patients with primary advanced or recurrent endometrial cancer (EC), dostarlimab plus…”
Get full text

EVALUATION OF HORMONAL FUNCTION IN WOMEN WITH CERVICAL INSUFFICIENCY AND INFERTILITY IN THE HISTORY by Perkhulyn, Oksana M, Pakharenko, Lyudmyla V, Sukhin, Vladyslav S, Saltovskiy, Oleksiy V, Kovalchuk, Viktoriia M, Hranovska, Hanna I, Kravchenko, Olha V

“…The aim: To assess the levels of hormones in women with cervical insufficiency and infertility in the history in the II trimester of gestation. Materials and…”
Get more information

Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists by Gultekin, Murat, Dursun, Polat, Vranes, Boris, Laky, Rene, Bossart, Michaela, Grabowski, Jacek P, Piek, Jurgen M J, Manchanda, Ranjit, Grimm, Christoph, Dallaku, Kastriot, Babloyan, Syuzanna, Moisei, Anna, Van Gorp, Toon, Cadron, Isabelle, Markov, Peter, Micevska, Ana, Halaska, Michael, Steffensen, Karina Dahl, Gristsenko, Liidia, Nissi, Ritva, Lambaudie, Eric, Tsitsishvili, Zaza, Haidopoulos, Dimitrios, Tsolakidis, Dimitrios, Novak, Zoltan, Peiretti, Michele, Dunenova, Gauhar, Macuks, Ronalds, Hetland, Thea E, Michelsen, Trond M, Martins, Filipe C, Achimas-Cadariu, Patriciu, Ulrikh, Elena A, Uharcek, Peter, Malic, Sladjana, Ognjenovic, Dejan, Zapardiel, Ignacio, Johann, Silke, Sukhin, Vladyslav S

“…The objectives of the study were to highlight some of the differences in training systems and opportunities for training in gynecologic oncology across Europe…”
Get more information

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial by Lorusso, Domenica, Xiang, Yang, Hasegawa, Kosei, Scambia, Giovanni, Leiva, Manuel, Ramos-Elias, Pier, Acevedo, Alejandro, Sukhin, Vladyslav, Cloven, Noelle, Pereira de Santana Gomes, Andrea J, Contreras Mejía, Fernando, Reiss, Ari, Ayhan, Ali, Lee, Jung-Yun, Saevets, Valeriya, Zagouri, Flora, Gilbert, Lucy, Sehouli, Jalid, Tharavichitkul, Ekkasit, Lindemann, Kristina, Lazzari, Roberta, Chang, Chih-Long, Lampé, Rudolf, Zhu, Hong, Oaknin, Ana, Christiaens, Melissa, Polterauer, Stephan, Usami, Tomoka, Li, Kan, Yamada, Karin, Toker, Sarper, Keefe, Stephen M, Pignata, Sandro, Duska, Linda R

“…Pembrolizumab has shown efficacy in persistent, recurrent, or metastatic cervical cancer. The effect of chemoradiotherapy might be enhanced by immunotherapy…”
Get full text

Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer by Randall, Leslie, Sukhin, Vladyslav, Colombo, Nicoletta, Korach, Jacob, Matsumoto, Takashi, Lalondrelle, Susan, Vizkeleti, Julia, Samouelian, Vanessa, Salani, Ritu, Salman, Pamela, Nogueira-Rodrigues, Angelica, Ayhan, Ali, Frentzas, Sophia, Cueva, Juan, Kim, Yong-Man, Petru, Edgar, Milla, Dency Pilar, Sehouli, Jalid, Saevets, Valeriya, Yamada, Karin, Li, Kan, Szamreta, Elizabeth, Nguyen, Allison Martin, Pignata, Sandro, Lorusso, Domenica

Get full text

Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial by Mirza, Mansoor Raza, Powell, Matthew A., Lundgren, Caroline, Sukhin, Vladyslav, Pothuri, Bhavana, Gilbert, Lucy, Gill, Sarah, Ronzino, Graziana, Nevadunsky, Nicole, Kommoss, Stefan, Willmott, Lyndsay, Boere, Ingrid, Mathews, Cara Amanda, Buscema, Joseph, Teneriello, Michael, Shahin, Mark S., Meyers, Oren, Garside, Jamie, Coleman, Robert L., Slomovitz, Brian M.

“…5504 Background: In RUBY, a phase 3, global, randomized, double-blind, placebo (PBO)-controlled trial, dostarlimab+carboplatin/paclitaxel demonstrated…”
Get full text

Impact of Hospital Case Volume on Uterine Sarcoma Prognosis: SARCUT Study Subanalysis by Gorostidi, Mikel, Yildirim, Yusuf, Macuks, Ronalds, Mancari, Rosanna, Achimas-Cadariu, Patriciu, Ibañez, Eduardo, Corrado, Giacomo, Bartusevicius, Arnoldas, Sukhina, Olena, Zapardiel, Ignacio

“…Background High-complexity and low-prevalence procedures benefit from treatment by referral centers. The volume of cases necessary to maintain high training in…”
Get full text

Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial by Lorusso, Domenica, Xiang, Yang, Hasegawa, Kosei, Scambia, Giovanni, Leiva, Manuel, Ramos-Elias, Pier, Acevedo, Alejandro, Sukhin, Vladyslav, Cloven, Noelle, Pereira de Santana Gomes, Andrea J., Mejía, Fernando Contreras, Reiss, Ari, Ayhan, Ali, Lee, Jung-Yun, Saevets, Valeriya, Zagouri, Flora, Gilbert, Lucy, Sehouli, Jalid, Tharavichitkul, Ekkasit, Lindemann, Kristina, Lazzari, Roberta, Chang, Chih-Long, Lampé, Rudolf, Zhu, Hong, Oaknin, Ana, Christiaens, Melissa, Polterauer, Stephan, Usami, Tomoka, Li, Kan, Yamada, Karin, Toker, Sarper, Keefe, Stephen M., Pignata, Sandro, Duska, Linda R.

“…(Abstracted from Lancet 2024;403:1341–1350) Prognosis for locally advanced cervical cancer is poor, with 5-year progression-free survival (PFS) and overall…”
Get full text

Prognostic factors in patients with uterine sarcoma: the SARCUT study by Zapardiel, Ignacio, Gracia Segovia, Myriam, Macuks, Ronalds, Mancari, Rosanna, Achimas-Cadariu, Patriciu, Corrado, Giacomo, Bartusevicius, Arnoldas, Sukhin, Vladyslav, Muruzabal, Juan C, Coronado Martín, Pluvio J, Gardella, Barbara, Piek, Jurgen M, Concin, Nicole, Arab, Clemente, Papatheodorou, Dimitrios, Polterauer, Stephan, Iacoponi, Sara, Nieto, Teresa, Lopez-Sanclemente, Martha C, Trukhan, Hanna, Gil, Maria M, Bakinovskaya, Irina, Dalamanava, Alena, Cucurull, Marc, Rovski, Dzmitry, Baquedano, Laura, Chiva, Luis, Mardas, Marcin, Mavrichev, Siarhei Anatolievich, Klat, Jaroslav, Lopez de la Manzanara, Carlos A, Yildirim, Yusuf

“…Uterine sarcomas are a rare and heterogeneous group of malignancies that include different histological sub-types. The aim of this study was to identify and…”
Get more information

Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee by Kurtz, Jean-Emmanuel, Gebski, Val, Sukhin, Vladyslav, Carey, Mark, Kong, Iwa, Glasspool, Rosalind M., Berek, Jonathan S., de Paiva Batista, Mariana, Hall, Marcia, Kim, Jae-Weon, Yeoshoua, Effi, Fujiwara, Noriko, Nam, Byung-Ho, Polleis, Sandra, Lee, Jung-Yun, Strojna, Aleksandra, Farrelly, Laura, Schwameis, Richard, Fossati, Roldano, Darlington, Anne-Sophie, Lai, Chyong-Huey, Wright, Alexi A., Rosenblat, Orgad, Harter, Phillip, Roxburgh, Patricia, Chowdhury, Rahul Roy, Chang, Ting-Chang, Paoletti, Xavier, Friedlander, Michael

“…Quality of life and patient reported outcome measures (PROMs) are important secondary endpoints and incorporated in most contemporary clinical trials. There…”
Get full text

SUCCOR quality: validation of ESGO quality indicators for surgical treatment of cervical cancer by Boria, Felix, Chiva, Luis, Chacon, Enrique, Zanagnolo, Vanna, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Shamistan, Aliyev, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Zusterzeel, Petra L M, Aluloski, Igor, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Bernardino, Margarida, Bharathan, Rasiah, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Demirkiran, Fuat, Vorgias, George, Povolotskaya, Natalia, Coronado Martín, Pluvio J, Marina, Tiermes, Zapardiel, Ignacio, Bizzarri, Nicolò, Gorostidi, Mikel, Gutierrez, Monica, Manzour, Nabil, Berasaluce, Arantxa, Martin-Calvo, Nerea

“…To evaluate whether compliance with European Society of Gynaecological Oncology (ESGO) surgery quality indicators impacts disease-free survival in patients…”
Get more information

SATEN III-Splitting Adjuvant Treatment of stage III ENdometrial cancers: an international, multicenter study by Kahramanoglu, Ilker, Meydanli, Mehmet Mutlu, Taranenka, Siarhei, Ayhan, Ali, Salman, Coskun, Sanci, Muzaffer, Demirkiran, Fuat, Ortac, Firat, Haidopoulos, Dimitrios, Sukhin, Vladyslav, Kaidarova, Dilyara, Stepanyan, Artem, Farazaneh, Farah, Aliyev, Shamistan, Ulrikh, Elena, Kurdiani, Dina, Yalcin, İbrahim, Mavrichev, Siarhei, Akilli, Huseyin, Sarı, Mustafa Erkan, Pletnev, Andrei, Aslan, Koray, Bese, Tugan, Kairbayev, Murat, Vlachos, Dimitrios, Gultekin, Murat

“…The purposes of this study were to compare adjuvant treatment modalities and to determine prognostic factors in stage III endometrioid endometrial cancer (EC)…”
Get more information

An infographic model of a database for conducting an analytical study of the long-term consequences of cervical cancer treatment by Radzishevska, Ye.B., Sukhina, О.М., Vasylyev, L.Ya, Sukhin, V.S., Nemaltsova, К.V., Solodovnikova, O.O.

“…Relevance. The development of ideas of critical attitude to medical information led to the concepts of evidence-based medicine (EM) in the late 1980s. The main…”
Get full text